Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.

PubWeight™: 0.89‹?›

🔗 View Article (PMID 10071916)

Published in Bone on March 01, 1999

Authors

P Ravn1, B Clemmesen, C Christiansen

Author Affiliations

1: Center for Clinical and Basic Research, Ballerup, Denmark.

Associated clinical trials:

Texture Analysis for Postmenopausal Osteoporosis | NCT00145977

Articles citing this

NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33

Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther (2011) 1.22

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol (2006) 1.20

Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet (2008) 1.06

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int (2007) 1.00

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int (2012) 0.99

An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int (2013) 0.90

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int (2003) 0.84

Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int (2015) 0.83

The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int (2008) 0.82

Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.81

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. Osteoporos Int (2009) 0.79

Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J (2013) 0.78

Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab (2009) 0.77

Tensile force on human macrophage cells promotes osteoclastogenesis through receptor activator of nuclear factor κB ligand induction. J Bone Miner Metab (2015) 0.75

Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns. J Bone Miner Metab (2013) 0.75

Articles by these authors

The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 9.71

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15

Bacterial genome sizes determined by DNA renaturation studies. J Gen Microbiol (1970) 5.86

Serological cross-reactions between Mycoplasma genitalium and Mycoplasma pneumoniae. J Clin Microbiol (1984) 3.15

Genome size of mycoplasmal DNA. Nature (1969) 2.86

Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76

Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J (1973) 2.60

Bone-density measurement. Lancet (1992) 2.38

Letter: Anticonvulsant hypomagnesaemia. Br Med J (1974) 2.30

Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ (1991) 2.12

Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest (1980) 2.04

Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med (1987) 2.03

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med (1999) 2.01

Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int (2002) 2.01

Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97

Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95

Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem (1994) 1.93

The sequence of 16S rRNA from Mycoplasma strain PG50. DNA (1985) 1.91

Circular, repetitive DNA in yeast. Biochim Biophys Acta (1972) 1.88

A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum (2004) 1.87

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81

Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med (1985) 1.81

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet (1981) 1.81

Catalysis of DNA reassociation by the Escherichia coli DNA binding protein: A polyamine-dependent reaction. J Mol Biol (1977) 1.73

Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66

Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability. Scand J Clin Lab Invest (1975) 1.65

Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int (2003) 1.63

Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61

Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res (1982) 1.59

Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis (1985) 1.54

Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem (1998) 1.51

The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric (2006) 1.50

Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage (2008) 1.50

Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med (2006) 1.49

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48

Accuracy of measurements of body composition by dual-energy x-ray absorptiometry in vivo. Am J Clin Nutr (1993) 1.48

Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone (1996) 1.45

Postmenopausal osteoporosis: therapeutic options. Climacteric (2005) 1.45

Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res (1990) 1.45

Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med (1993) 1.44

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone (2012) 1.42

Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int (1991) 1.42

Circular DNA molecules controlling synthesis and transfer of the surface antigen (K88) in Escherichia coli. J Gen Microbiol (1972) 1.41

Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41

Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol (1991) 1.41

Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis (2003) 1.40

Incorporation and distribution of strontium in bone. Bone (2001) 1.40

Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40

Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism (1991) 1.40

Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40

Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res (1991) 1.37

Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers (2009) 1.37

Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab (1987) 1.36

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone (2002) 1.35

Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ (1989) 1.34

Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int (2006) 1.33

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab (1988) 1.33

Mechanism of circadian variation in bone resorption. Bone (2002) 1.33

Effect of puberty on rates of bone growth and mineralisation: with observations in male delayed puberty. Arch Dis Child (1979) 1.31

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30

Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis (1999) 1.29

Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) (1989) 1.29

Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet (1978) 1.29

Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes (1984) 1.28

Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28

Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism (1995) 1.28

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ (1992) 1.27

Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin Rheumatol (1984) 1.27

Calcium supplementation and postmenopausal bone loss. Br Med J (Clin Res Ed) (1984) 1.27

Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care (1995) 1.26

The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery (1974) 1.25

Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone (2000) 1.24

Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol (Oxf) (1982) 1.24

Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy (2009) 1.24

Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 1.23

Bone changes occurring spontaneously and caused by estrogen in early postmenopausal women: a local or generalised phenomenon? Br Med J (Clin Res Ed) (1986) 1.22

Usefulness of regional bone measurements in patients with osteoporotic fractures of the spine and distal forearm. J Nucl Med (1987) 1.21

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20

The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum (1985) 1.19

Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta (1982) 1.19

Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med (1985) 1.19

Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage (2006) 1.19

Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest (1977) 1.19

Body composition and calcium metabolism in adult treated coeliac disease. Gut (1991) 1.18

Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res (1999) 1.18

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17

Lithium, hypercalcemia, hypermagnesemia, and hyperparathyroidism. Lancet (1976) 1.17

The mineral content in bone. Measured by means of 27.5 keV radiation from 125I. Acta Radiol Suppl (1972) 1.16

Separation of healthy and early osteoarthritis by automatic quantification of cartilage homogeneity. Osteoarthritis Cartilage (2007) 1.16

Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? Bone (2003) 1.16

Classification of the F38 group of caprine Mycoplasma strains by DNA hybridization. J Gen Microbiol (1982) 1.16

Management of hypersensitivity reactions to iodinated contrast media. Allergy (2005) 1.16

Transplantation of the parathyroid glands in dogs. Biochemical, histological, and radioimmunoassay proof of function. Transplantation (1973) 1.16